Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Conestoga's high-quality growth composites underperformed their benchmarks in 4Q25 and full year 2025 due to a narrow, speculative, and highly concentrated market rally favoring unprofitable, high-beta ('low quality') companies and biotech/pharma stocks in which Conestoga was structurally underweight. Despite these headwind-driven...
— Conestoga Capital Advisors, LLC
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on West Pharmaceutical Services
The fund completely exited its stake in West Pharmaceutical Services Inc. during the quarter.
Our investment case for West Pharmaceutical Services is clear: West sits in a uniquely strong position within a structurally growing industry, with the potential to create huge sustaina
Our investment case for West Pharmaceutical Services is clear: West sits in a uniquely strong position within a structurally growing industry, with the potential to ...